NTHU
2.12.2021 11:02:13 CET | Business Wire | Press release
National Tsing Hua University (NTHU) was awarded the Taiwan University Sustainability Award at the 14th Taiwan Corporate Sustainability Awards (TCSA) held by the Taiwan Institute for Sustainable Energy (TAISE) on November 17. Standing out amongst the 38 participating universities, NTHU was ranked first in the comprehensive evaluation, and in the individual competitions also received the Social Inclusion Leadership Award and the University Sustainability Report Gold Award.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005031/en/
The judges cited the exemplary way in which NTHU has built on its core competence in teaching and research to respond with concrete actions in meeting the requirements of sustainable development, including the implementation of a campus-wide campaign for reducing energy consumption and carbon emissions. In addition, they were impressed by NTHU’s workplace ethics emphasizing diversity and equality, as well as the way in which faculty and staff are rewarded for outstanding performance in research, teaching, counseling, and public service, all of which has had a positive impact on the larger society and enhanced the university’s international profile. In terms of sustainability, NTHU has consistently demonstrated what is meant by its school motto, “To Oneself Be True, Give Nature Its Due.”
President Hocheng Hong said that the natural beauty of the campus goes hand-in-hand with the principles of sustainability. In addition to being the first university in Taiwan to appoint a chief sustainability officer, NTHU has a total of 517 undergraduate courses related to sustainability, and 216 at the graduate level, which together amount to 13% of the school’s courses.
NTHU senior vice president and chief sustainability officer Tai Nyan-hwa pointed out that in order to deepen the concept of sustainability on all levels, each administrative and academic department has appointed a sustainability officer, all 26 of whom belong to the Sustainability Committee, which meets every two months to discuss the latest developments and coordinate their efforts.
Sustainability Office director Lin Fu-ren said that since research, teaching, and public service are the most important tasks of a university, the school’s early efforts in promoting sustainability focused on encouraging teachers, researchers, and students to integrate the principles of sustainability into their ongoing work. Numerous faculty members at NTHU are conducting research directly related to the 17 goals of sustainable development promulgated by the United Nations. In the process, they have demonstrated how focusing attention on an issue generates positive change.
Lin said that in addition to the ongoing Rising Sun Scholarship for financially disadvantaged students, NTHU has established a special fund for assisting students undergoing hardship due to the COVID-19 pandemic, both of which tie in with the UN’s sustainability goals of “no poverty” and “quality education.”
Lin also pointed out that making sustainable development a reality requires planting the seeds of sustainability in the hearts of students, so that when they graduate, these seeds will sprout and grow strong throughout society.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005031/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom